Patents by Inventor R. Michael Lawrence

R. Michael Lawrence has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10695328
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: June 30, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Publication number: 20200123160
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: August 13, 2019
    Publication date: April 23, 2020
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Patent number: 10590113
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: March 17, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zulan Pi, Donna M. Bilder, Robert Paul Brigance, Heather Finlay, Wen Jiang, James A. Johnson, R. Michael Lawrence, Wei Meng, Michael C. Myers, Monique Phillips, George O. Tora, Xiaojun Zhang
  • Publication number: 20190314346
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: June 19, 2019
    Publication date: October 17, 2019
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Patent number: 10428077
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: October 1, 2019
    Assignees: Bristol-Myers Squibb Company, Université de Montréal
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Publication number: 20190263791
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Application
    Filed: May 14, 2019
    Publication date: August 29, 2019
    Inventors: James A. Johnson, Soong-Hoon Kim, R. Michael Lawrence, Michael C. Myers, Hannguang J. Chao, Monique Phillips, Ji Jiang
  • Patent number: 10392347
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: August 27, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Soong-Hoon Kim, Hannguang J. Chao, Heather Finlay, Ji Jiang, James A. Johnson, R. Michael Lawrence, Michael C. Myers, Monique Phillips, George O. Tora, Wei Meng
  • Publication number: 20190256570
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Application
    Filed: February 27, 2019
    Publication date: August 22, 2019
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Patent number: 10369140
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: August 6, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Patent number: 10266578
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: April 23, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Publication number: 20190002441
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 3, 2019
    Inventors: Zulan Pi, Donna M. Bilder, Robert Paul Brigance, Heather Finlay, Wen Jiang, James A. Johnson, R. Michael Lawrence, Wei Meng, Michael C. Myers, Monique Phillips, George O. Tora, Xiaojun Zhang
  • Publication number: 20180362508
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments, in particular for treating cardiovascular disorders.
    Type: Application
    Filed: December 15, 2016
    Publication date: December 20, 2018
    Inventors: Michael C. Myers, R. Michael Lawrence, Donna M. Bilder, Wei Meng, Zulan Pi, Robert Paul Brigance, Heather Finlay
  • Publication number: 20180305376
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: June 27, 2018
    Publication date: October 25, 2018
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Patent number: 10106528
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: October 23, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zulan Pi, Donna M. Bilder, Robert Paul Brigance, Heather Finlay, Wen Jiang, James A. Johnson, R. Michael Lawrence, Wei Meng, Michael C. Myers, Monique Phillips, George O. Tora, Xiaojun Zhang
  • Publication number: 20180297954
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, O and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Application
    Filed: October 13, 2016
    Publication date: October 18, 2018
    Inventors: Soong-Hoon Kim, Hannguang J. Chao, Heather Finlay, Ji Jang, James A. Johnson, R. Michael Lawrence, Michael C. Myers, Monique Phillips, George O. Tora, Wei Meng
  • Publication number: 20180273518
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Application
    Filed: May 29, 2018
    Publication date: September 27, 2018
    Inventors: James A. Johnson, Soong-Hoon Kim, R. Michael Lawrence, Michael C. Myers, Hannguang J. Chao, Monique Phillips, Ji Jiang
  • Patent number: 10047103
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: August 14, 2018
    Assignees: Bristol-Myers Squibb Company, Universite de Montreal
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Publication number: 20180222960
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 9, 2018
    Inventors: Gene M. DUBOWCHIK, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Patent number: 10011594
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: July 3, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: James A. Johnson, Soong-Hoon Kim, R. Michael Lawrence, Michael C. Myers, Hannguang J. Chao, Monique Phillips, Ji Jiang
  • Publication number: 20180133198
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 17, 2018
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao